Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2025-12-25 @ 12:01 AM
NCT ID: NCT03051958
Eligibility Criteria: Inclusion Criteria: * Fulfills the diagnostic criteria for atopic dermatitis in accordance with Williams criteria 1994 * at the time of inclusion the eczema should be at least moderate according to The Patient Oriented Eczema Measure (POEM) * Regular access to computer and internet connection * If on antidepressant or regular sleep medication, the medication should be stable for at least one month prior to inclusion and the person should be willing to keep the medication stable throughout the study * possibility to actively carry out the treatment (not go for longer journeys, do homework) * good understanding of written and spoken Swedish Exclusion Criteria: * severe psychiatric illness (bipolar disorder, schizophrenia or other psychotic illness, substance, alcohol abuse, severe depression, suicide risk) * difficulties with reading or writing * ongoing treatment for cancer * pregnancy * other psychological treatment that i ongoing or recently terminated * stronger anxiety-reducing medication such as benzodiazepines * treatment with antibiotics that is ongoing or has been terminated less than one month prior to inclusion * Psoriasis * UV-light treatment that is ongoing or has been terminated less than one month prior to inclusion * oral treatment for eczema that is ongoing or has been terminated less than two month prior to inclusion
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 60 Years
Study: NCT03051958
Study Brief:
Protocol Section: NCT03051958